Pharmascroll has been a renowned Syndicated and customized research provider across the Healthcare and Pharmaceutical space. Pharmascroll has generated over 75 market research reports and has consulted several Global clients across multiple areas.

The report delivers an in-depth understanding of the disease, historical & forecasted epidemiology and market size drug wise for Schizophrenia with a forecast till 2024.

The report delivers an in-depth understanding of the disease, historical & forecasted epidemiology and market size drug wise for Epilepsy disease with a forecast till 2024.

The report delivers an in-depth understanding of the disease, historical & forecasted epidemiology and market size drug wise for Parkinson’s disease with a forecast till 2024.

The report delivers an in-depth understanding of the disease, historical & forecasted epidemiology and market size drug wise for Asthma disease with a forecast till 2024.

The report delivers an in-depth understanding of the disease, historical & forecasted epidemiology and market size drug wise for COPD disease with a forecast till 2024.

The report delivers an in-depth understanding of the disease, historical & forecasted epidemiology and market size drug wise for Cystic Fibrosis disease with a forecast till 2024.

The report delivers an in-depth understanding of the disease, historical & forecasted epidemiology and market size drug wise for Alzheimer’s disease with a forecast till 2024.

Pharmascroll to offer Monthly Market Intelligence reports on multiple disease indications both on a standalone and subscription basis.

“PPMS and SPMS: Epidemiology and Market Forecasts to 2030” reports cover in depth disease insights, epidemiology overview and markets and drug forecasts country wise till 2030

Pharmascroll, on the back of its successful engagement with Market Research clients and enhanced capabilities, has announced to expand its operations across multiple disease areas

Expected launch of Siponimod & a strong pipeline in SPMS indicates a strong SPMS focus. SPMS- Detailed overview provides SPMS overview, highlights SPMS epidemiology, elaborates on the drugs in SPMS along with the sales and patient numbers forecast

Expected launch of Siponimod & a strong pipeline in SPMS indicates a strong SPMS focus. SPMS- Detailed overview provides SPMS overview, highlights SPMS epidemiology, elaborates on drugs in SPMS along with sales and patients forecast

Pharmascroll plans to offer quality Market Research and Consulting to the Pharmaceutical firms researching and operating in Chronic disease indications at affordable prices

Pharmascroll, currently a renowned Syndicated Research provider, has announced entry into the customized Pharmaceutical Marketing research space

Pharmascroll, a Market Research and Business Consulting firm, has come up with an extensive range of portfolio with the launch of over 30 reports in multiple indications

Market Publishers Ltd and Pharmascroll Research and Consulting signed a partnership agreement for quality market research promotion on Internet

Nearly 50% of RRMS patients progress to SPMS in a 10 year time period indicating a huge market potential. However in present scenario, not many drugs are approved in the SPMS market indicating a huge unmet need.

All anti CGRP molecules have displayed similar efficacy and safety during trials. The products are expected to gain majority shares in Migraine market given their superior efficacy and safety profiles as compared to the existing therapies.

aCGRP molecules launch is expected to shift the momentum from acute therapies to preventive treatments. Migraine- Detailed overview gives Migraine overview, highlights epidemiology, mentions Migraine drugs with sales & patient numbers forecast

Strong pipeline in PPMS indicates a paradigm shift in progressive space. PPMS- Detailed overview gives PPMS overview, highlights PPMS epidemiology, mentions drugs expected to be prescribed with the sales & patient numbers forecast